Keyword: Ironwood Pharmaceuticals
Rare disease biotech Cyclerion has poached Shire’s ex-head of R&D, Andy Busch, Ph.D., as its new chief innovation officer, less than 18 months after he joined the company from his long stint at Bayer.
Ironwood will walk away from its deal for AstraZeneca’s billion-dollar gout treatment lesinurad, following poor market performance.
Ironwood plans to split into two independent companies, spinning off some of its R&D work into a yet-unnamed business in the first half of 2019.
Ironwood Pharmaceuticals unveiled promising topline data from phase 2a trials investigating its sGC stimulator in patients with Type 2 diabetes and hypertension.
CSO Hayden will leave as Teva restructures, Bayer R&D reorg sees Moeller in and Busch out for Shire, Shire and Biogen get experienced CFOs.
Ardelyx now has a second positive phase 3 trial for its constipation-predominant irritable bowel syndrome drug tenapanor.
R&D chief Narsimhan will replace retiring Jimenez as Novartis CEO, Stada names its fourth CEO in less than two years, Vertex poaches CFO from Ironwood.
The positive narrative spun by Ironwood’s management failed to convince investors, who seized on perceived underwhelming efficacy data.
Sanofi Genzyme's CEO Meeker will step down amid key rollouts, Allergan's chief strategy officer Patel became CEO at startup Relay, and more.
Ironwood is already chalking up success with its first colonic delivery drug Linzess, but analysts reckon another payoff could come from two follow-up drugs.